Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBT Margin (2023 - 2025)

Historic EBT Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 445.67%.

  • BioLineRx's EBT Margin fell 3695600.0% to 445.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 108.68%, marking a year-over-year increase of 499300.0%. This contributed to the annual value of 66.63% for FY2024, which is 9925800.0% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's EBT Margin is 445.67%, which was down 3695600.0% from 666.78% recorded in Q2 2025.
  • In the past 5 years, BioLineRx's EBT Margin registered a high of 1505.71% during Q1 2023, and its lowest value of 1716.63% during Q4 2023.
  • Its 3-year average for EBT Margin is 374.15%, with a median of 260.89% in 2025.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's EBT Margin was 16490600bps (2024), while the steepest drop was -15625000bps (2024).
  • Over the past 3 years, BioLineRx's EBT Margin (Quarter) stood at 1716.63% in 2023, then surged by 96bps to 67.57% in 2024, then tumbled by -560bps to 445.67% in 2025.
  • Its last three reported values are 445.67% in Q3 2025, 666.78% for Q2 2025, and 772.94% during Q1 2025.